5-Amino-1MQ Explained: Mechanism, Mouse Studies and Status

No. A peptide is a chain of amino acids linked by peptide bonds — the class of molecule behind compounds like BPC-157 or thymosin alpha-1. 5-Amino-1MQ is structurally unrelated: it is a small heterocyclic organic molecule, a substituted quinolinium salt, with no amino acid backbone and no peptide bond anywhere in it. Chemically, it has more in common with a small-molecule drug than with a peptide hormone.^[4]

That difference is functional as well as structural. Structure-activity research on this compound class describes 5-Amino-1MQ sitting inside NNMT's nicotinamide-binding pocket and blocking the enzyme directly there, with a reported potency of about 1.2 micromolar (IC50) against the isolated enzyme. A peptide medicine typically works by mimicking or blocking a hormone at a cell-surface receptor; 5-Amino-1MQ's target is an intracellular metabolic enzyme, not a receptor.^[4]

Nicotinamide N-methyltransferase (NNMT) is an enzyme most active in fat tissue and liver. Its normal job is to attach a methyl group to nicotinamide — a form of vitamin B3, and the same molecule the body's main NAD+ salvage pathway recycles back into NAD+ — converting it into 1-methylnicotinamide. NNMT takes that methyl group from S-adenosylmethionine (SAM), the cell's principal methyl donor for hundreds of other reactions, and releases S-adenosylhomocysteine (SAH) as a by-product.^[3]

That one reaction sits at the crossing point of two systems obesity research has focused on. By methylating nicotinamide, NNMT removes it from the pool available to regenerate NAD+, the coenzyme cells need for energy metabolism and hundreds of other enzymatic reactions. By consuming SAM and releasing SAH, high NNMT activity also lowers the cell's SAM-to-SAH ratio — a measure of how much spare methylation capacity is left for other reactions, including DNA and histone methylation. Published review literature reports NNMT activity as elevated in obese fat tissue, which is the basis for testing whether blocking the enzyme changes metabolism.^[3]

5-Amino-1MQ is designed to interrupt that reaction rather than supplement anything: by occupying NNMT's nicotinamide-binding site, it blocks the enzyme directly. In cultured fat cells, this lowered levels of 1-methylnicotinamide — the product NNMT normally makes — while raising intracellular NAD+ and SAM, the reverse of what high NNMT activity does.^[1]

The first in-vivo test of 5-Amino-1MQ, published by Neelakantan and colleagues in Biochemical Pharmacology in 2018, used diet-induced obese male C57BL/6 mice that had been fed a high-fat diet for a total of 16 weeks before they were randomised to treatment. Nine mice per group received either 5-Amino-1MQ — three subcutaneous injections a day, roughly 34 mg/kg total per day — or vehicle, for 11 days, while staying on the same high-fat diet. Treated mice lost about 5.1% of body weight while control mice gained about 1.4% (p < 0.0001 by days 9–10), alongside roughly 35% less epididymal fat-pad mass, over 30% smaller fat cells, and about 30% lower plasma cholesterol than controls — all without any measured change in food intake.^[1]

A follow-up study by an overlapping author group, published in Scientific Reports in 2022, tested whether combining 5-Amino-1MQ with a diet change worked better than either alone. Diet-induced obese mice (6–8 per group) were switched from a high-fat diet to a lower-fat diet and given 5-Amino-1MQ (about 32 mg/kg per day, subcutaneous) for roughly seven weeks; the combination group's body weight and fat mass became statistically indistinguishable from lean control mice, and the treated group developed a distinct gut-microbial community — including more Lactobacillus — compared with mice given the diet change alone.^[2]

No. A search of the U.S. National Library of Medicine's ClinicalTrials.gov registry for '5-amino-1-methylquinolinium', '5-amino-1MQ' and 'NNMT inhibitor' returns no registered studies of any kind — not completed, not recruiting, not withdrawn. As of September 2026, nothing about 5-Amino-1MQ's effect, safety or dosing in people has been tested in a registered clinical study.^[6]

That matters because everything reported about 5-Amino-1MQ so far — the weight and fat-mass changes, the cholesterol and adipocyte findings, the microbiome shifts — comes from short-term, high-dose injections in obese mice. Mouse pharmacology does not reliably predict a compound's human dose, safety margin or effect size, and no published bridging work, such as a human pharmacokinetic study, exists for 5-Amino-1MQ.^[1][2]

5-Amino-1MQ has no FDA approval as a drug or as a dietary ingredient. The clearest FDA statement on it to date is a warning letter, dated 20 January 2026, sent to a Florida compounding facility, GenoGenix LLC. In it, the FDA named '5-amino-1-methylquinolinium iodide (5-Amino-1MQ)' directly and stated that it does not appear on the FDA's list of bulk drug substances that outsourcing facilities may use under section 503B of the Food, Drug and Cosmetic Act, and was not being used to compound a medicine on the FDA's drug-shortage list — so the facility's use of it did not qualify for that section's compounding exemption.^[5]

In the European Union, the European Medicines Agency's public database of authorised medicines lists no marketing authorisation for 5-Amino-1MQ, or for any medicine built on it, under any brand name, as of September 2026. Together with the absence of any registered clinical study, that leaves 5-Amino-1MQ without approval as a medicine anywhere Peptyds operates, consistent with it being sold online as an unapproved research chemical rather than as an authorised medicine.^[7]

No. Peptyds does not supply 5-Amino-1MQ. This article exists because the compound is widely discussed online under peptide-adjacent marketing, and because 'is 5-Amino-1MQ a peptide' is itself a common search question; the honest answer is no, for the structural reasons described above.

Peptyds does supply peptides for laboratory research, including compounds discussed in the articles linked below for readers who want the broader context: what a peptide actually is chemically, how that differs from a polypeptide or protein, and how NAD+ — another frequently confused, non-peptide research compound — fits into the same metabolic and longevity research conversation as NNMT.